Mounjaro
Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes (T2D) and for weight loss. Tirzepatide is administered via subcutaneous injections. It is sold in several countries under the brand name Mounjaro for T2D treatment. In the United States, it is sold under the brand name Zepbound for weight loss and for the treatment of obstructive sleep apnea.
Beyond's analysis on Mounjaro
- — South Koreans cross into Japan to buy cheaper Mounjaro, exposing price arbitrage and supply‑chain pressure for the obesity drug
- — GLP-1 weight-loss drugs face scrutiny over reported side‑effects like ‘Ozempic face’ and hair loss
- — France's decision to reimburse two anti-obesity drugs introduces complex cost-benefit calculations for the national health insurance system
Recent news mentioning Mounjaro
- — South Koreans are sneaking cheap Mounjaro home from Japan to lose weight
- — La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2
- — FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes